Small Caps
23 May
Avacta reports further progress in chemotherapy trial
Avacta Group announced the successful completion of the first cohort and the start of dosing for three patients in the second cohort of the second arm in its phase one trial of AVA6000, a peptide drug conjugate form of doxorubicin chemotherapy, on Thursday.
23 May
Cohort ends year slightly ahead of expectations
Technology company Cohort said in a trading update on Thursday that its full-year performance was slightly ahead of expectations, with growth in both revenue and profits year-on-year.